Clinical Trial

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-19; most recent amendment 2026-05-18.
Status change: Not Yet Recruiting → Recruiting 2025-11-13
Trial Details
NCT Number NCT07133425
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Sanofi
Conditions Non-Small Cell Lung Cancer, ICI-refractory
Enrollment 29 participants
Start Date 2025-11-06
Primary Completion 2028-02-01 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29